Oral piritrexim, an effective treatment for metastatic urothelial cancer.
Piritrexim is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells rapidly by passive diffusion, cannot be polyglutamated, and is as effective as methotrexate in inhibiting DHFR. Bioavailability after oral dosing is approximately 75%. We performed a phase II study wit...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
1993
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968166/ |